Skip to main content
OpenTrials
Completed

NCT Number: NCT05271981

Fertility After Uterine Artery Embolization

Uterine leiomyomas (or fibroids) are a common disease (30% of women over 35 years of age) in women of childbearing age and can cause various symptoms such as menometrorrhagia, dysmenorrhoea, pelvic pain and heaviness, and infertility.

Uterine artery embolisation, first used in France in 1990, is a safe, effective and less invasive therapeutic technique than surgical treatment (myomectomy or hysterectomy), particularly in the case of numerous and large fibroids. This technique is validated by the French National College of Gynaecologists-Obstetricians (CNGOF) as an alternative treatment for women who do not wish to become pregnant (grade A recommendation), but at present there is little reliable data concerning fertility, the occurrence of pregnancy and the obstetrical prognosis after uterine artery embolisation for fibroids. A recent systematic review of the literature with meta-analysis published very recently showed that 40.5% of patients with a desire for pregnancy were able to become pregnant after embolisation (CI: 33.3%-48.2%) but that the rates of miscarriage, obstetric complications and low birth weight were not negligible (respectively 33.5% (95% CI: 26.3-41%), 25.4% (95% CI = 13-40.2%) and 10% (95% CI = 6.2-14.6%) (Ghanaati et al. 2020).

In France, uterine artery embolisation is performed in more than thirty centres in women who have completed their parental project. On the other hand, in the absence of consistent literature, it is performed in patients of childbearing age, when it represents the only acceptable alternative or in the event of contraindication or refusal of surgery by the patient. To our knowledge, there is no large-scale French study to date on the impact of embolisation on fertility and pregnancy outcomes.

The aim of this study is to compile a retrospective database of all cases of uterine artery embolisation for uterine pathology performed at the Georges-Pompidou European Hospital (HEGP) since 2007 and to assess the impact of embolisation on fertility in patients of childbearing age.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women ≥ 18 years, ≤ 45 years at the time of their embolisation
  • Uterine pathology responsible for disabling symptoms: uterine leiomyomas with no limitations in size, number or location, adenomyosis
  • Having had a uterine artery embolisation between 2007 and September 2020
  • Minimum delay of one year after embolisation
  • Information and no opposition from patients

Exclusion criteria

  • Women < 18 years and > 45 years at the time of embolisation
  • Uterine artery embolisation for delivery haemorrhage
  • Patients under court protection, guardianship or curatorship
  • Refusal to participate in this research

Treatment and study plan

Retrospective data collection

Other

Data collection from the medical file of the patients

Phone Interview

Other

Call for collecting fertility data and obstetrical issues of the patients

Primary outcomes

  1. Rate of live births after embolisation

    Time frame: one year

    Rate of live births after embolisation (percentage)

Secondary outcomes

  1. Obstetrical outcomes after embolisation

    Time frame: one year

    • Pregnancy rate (percentage) ;
    • Miscarriage rate (percentage) ;
    • Assisted reproduction rate;
    • Obstetric complication rates (haemorrhage, caesarean section, prematurity, pre-eclampsia, placental disorders)
  2. Effectiveness and safety of embolisation

    Time frame: one year

    • Complication rate of embolisation (percentage)
    • Post-embolisation myomectomy and hysterectomy rates (percentage)

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Collège National des Gynécologues et Obstétriciens Français
  • Gedeon Richter France

Registry information

Official study title

Uterine Artery Embolization For Uterine Pathology: What Impact On Fertility?

Acronym: FERTI-EMBOL

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 9, 2022
Registry last updated
Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.